Scott Power: ASX health stocks fall in ‘lacklustre week'
ASX heath sector falls 1.1% over past five days
The US FDA approves CSL's Andembry to prevent attacks of hereditary angioedema
Clever Culture systems records its second consecutive quarter of positive cashflow operations
Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his take on the ASX healthcare sector for the week and his 'Powerplay' stock pick.
The ASX healthcare sector has had what Morgans' senior healthcare analyst Scott Power described as a "lacklustre week".
At lunchtime on Friday, the S&P/ASX 200 Health Care index (ASX:XHJ) was down 1.1% for the past five days, while the benchmark S&P/ASX 200 (ASX:XJO) fell 0.55% for the same period.
Markets have been influenced by global economic and geopolitical concerns, particularly escalating tensions between Iran and Israel.
And it seems US President Donald Trump has not backed down from tariffs on pharmaceutical imports.
A United States Department of Commerce investigation is underway under Section 232 of the Trade Expansion Act of 1962 – a provision that allows the president to restrict imports if they are deemed a threat to national security.
Returning from the G7 Summit in Canada Trump reportedly told media on Air Force One tariffs on the sector were coming.
"We're going to be doing pharmaceuticals very soon," he said.
"That's going to bring all the companies back into America... at least partially back in."
Power said Trump's latest comments were adding further jitters to the sector.
"Until we get clarity there's going to be volatility," he said.
Power's Powerplay – CSL gets FDA approval for Andembry
The ASX's largest healthcare stock CSL (ASX:CSL) has notched a milestone with the FDA approving its Andembry (garadacimab) to prevent attacks of hereditary angioedema (HAE).
Affecting about one in 50,000 people CSL said HAE was the first and only treatment targeting factor XIIa for prophylactic use to provide sustained protection from attacks of HAE in adult and pediatric patients aged 12 years and older.
The approval was based on a pivotal phase III (VANGUARD) trial and ongoing open-label extension study, showing Andembry reduced the median number of HAE attacks by more than 99% (mean 89.2%), compared to placebo.
Andembry is also the only treatment to offer once-monthly dosing from the start for all patients and is administered via an autoinjector.
The drug is already available in Australia, the UK, EU, Japan, Switzerland and UAE.
CSL said Andembry will be launched "immediately", with availability through third-party specialty pharmacy network before the end of June.
In a note to clients, Morgans' healthcare analyst Derek Jellinek wrote that while Andembry's US approval had taken longer than expected, with application filing in December '24, it's good to see the drug greenlit before the end of '25 "despite the ongoing tumultuous environment" at the US Food and Drug Administration at the agency.
"We view Andembry's unique MOA (ie upstream inhibition of key pathways leading to HAE attacks, so broader applicability), favourable safety profile and convenient dosing (every 4 weeks via subcutaneous injection) as key differentiators," Jellinek wrote.
While Andembry is expected to impact Berinert sales – CSL's treatment for acute HAE attacks – Jellinek believes the effect should be modest.
He wrote Berinert's revenue was forecast to remain steady in FY25 at US$242 million, accounting for less than 2% of CSL's total revenue. Sales are projected to ease slightly to US$230m in FY26 and US$225 million in FY27.
However, this is more than compensated by anticipated growth in Andembry sales, which are expected to reach US$120m in FY26 and increase to US$220m in FY27.
Morgans has an add rating on CSL and 12-month target price of $329.26.
Clever Culture Systems delivers clever Q3 FY25 result
Clever Culture Systems (ASX:CC5) has achieved its second consecutive quarter of positive cashflow operations with $500,000 net cash inflow in Q3 FY25 and is on track to achieve break-even or better for H2 FY25.
During the quarter Clever Culture continued to execute on its commercialisation strategy for its APAS Independence instruments
in the pharmaceutical market, building on success with big pharma companies Astra Zeneca and Bristol Myers Squibb (BMS).
The instruments use artificial intelligence and machine learning software to automate the imaging, analysis and interpretation of microbiology culture plates.
Since launching the product in March 2024, Clever Culture said it had completed sales and received orders from pharmaceutical customers for 13 APAS instruments, representing ~$6 million in revenue with a pipeline of 40 qualified opportunities.
Clever Culture finished Q3 FY25 with a cash position of $2.2m.
"Other top 10 pharmaceutical companies are expected to engage with CC5 following the AstraZeneca and Bristol Myers Squibb success," Power said.
Emvision awarded $5 million government grant
EMVision Medical Devices (ASX:EMV) has been awarded a $5 million federal government grant to further development of its First Responder portable brain scanner.
The funds are by way of an Australian government Industry Growth Program (IGP) Commercialisation and Growth Grant.
First Responder is EMVision's second product and distinguishes between bleed and clot strokes at the scene and is designed to be used by ambulances and by paramedics.
The device should shorten diagnosis time, a crucial element in the patient getting the right treatment.
EMVision's first commercial device – the emu bedside brain scanner – is also designed to rapidly diagnose stroke at the point-of-care with a pivotal trial underway to supports US Food and Drug Administration (FDA) de novo (new device) clearance.
Audeara hits record, Micro-X gets milestone payment boost
In other news of the week, specialist in listening solutions for people with hearing challenges Audeara (ASX:AUA) has delivered record revenue exceeding $3.64 million for the 11 months to end of May FY25.
Audeara reported revenue for the 11-month period was up 14% on FY24 total revenue and 25% on FY23, which the company said signalled underlying strength of its ongoing operations.
The company expects additional growth to materialise in coming weeks based on strong June 2025 trading.
And leader in cold cathode x-ray technology for health and security markets Micro-X (ASX:MX1) has received $2.3 million in milestone payments for two projects.
MicroX achieved milestone three under its development agreement with US Advanced Research Projects Agency for Health (ARPA-H) and Department of Homeland Security (DHS) for a full body CT scanner, delivering $1.4 million.
The company also achieved milestone two under a strategic partnership deal with Billion Prima for a baggage and parcel scanning unit due for completion in 2025, delivering $900,000.
"We are pleased to continue to deliver strong progress on these key development contracts with ARPA-H, DHS, and Billion
Prima respectively, which is a testament to our focus and timely delivery on key projects," Micro-X CEO Kingsley Hall said.
"We are also well advanced with the final stages of our Head CT development as we prepare to enter human imaging trials."
The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead.
Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article.
At Stockhead, we tell it like it is. While Clever Culture Systems, Audeara and EMVision are Stockhead advertisers, the companies did not sponsor this article.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
29 minutes ago
- News.com.au
Katherine Heigl's candid bathroom confession praised
One of Hollywood's biggest stars has been praised for throwing her weight behind a health topic that is typically considered taboo. Katherine Heigl, known for her roles in Grey's Anatomy, Firefly Lane and 27 Dresses, has teamed up with healthcare brand Poise to speak about bladder leakage and perimenopause. In a video shared to Instagram, Heigl speaks directly to her Australian fans. 'As you know, I am not one to shy away from speaking out and so now I am speaking directly to you,' she said. 'When Poise came to me and said that the prevalence of bladder leakage is even higher in Australia with two in three women over 25 experiencing what I like to call the old 'giggle dribble' I wanted to do a special call out to my fans Down Under. 'Those post-partum or perimenopause bladder leaks are so common but often not talked about and so I thought this was an excellent opportunity to get outspoke once again. I don't want a single woman out there to feel alone in this experience or to feel shame or embarrassment. I refuse to let a little giggle dribble stop me from doing everything it means to be a woman and a mother.' Heigl, 46, said that was why she was excited to bring her Poise campaign to Australian televisions — and women who have seen it have praised the actress for her openness. 'I was thrilled to see a pretty and popular actress talking about this so openly on TV. I mean the bar is low right now, but, hearing her say 'perimenopause' AND speak so openly about leaks and peri in front of her male child in the commercial is a step in the right direction IMO,' one viewer said. Another said: 'Obsessed with Katherine Heigl! Love that she is talking about such a taboo topic, go Poise!' 'Great to see this topic being spoken about more openly,' one added. One social media user chimed in: 'Hard relate!' 'Such an important issue,' another agreed. Heigl went on share more about her own experience with bladder leakage, with the Emmy Award winner revealing her first experience with it happened after the birth of her son Joshua in 2017. 'I was just like, 'Oh, excuse me, I'm going to need to go change my underwear'. I kind of just laughed through it versus feeling shame. But then you start going through perimenopause and it's just all falling apart. So you just have to embrace it,' she said. She reiterated that she wasn't OK with anyone feeling any kind of shame or embarrassment around it as it's a natural part of being a woman. 'And it's such a blessing to have a product that can support you through that,' she said. 'Just having someone else who's going through it or having similar experiences makes you feel like, okay, it's not just me. It's kind of universal – which is why I feel strongly that there should be more proactive help for all of us women going through this.'
News.com.au
2 hours ago
- News.com.au
Criterion: Back up the dumpster! It's time for an EOFY share purge
Potential tax loss selling candidates include ASX200 inclusions Domino's Pizza Enterprises and IDP Education Investors may want to offset capital gains from successful AI and Trump-related plays But beware: tax-loss selling is governed by ATO rules Tax-loss selling is a fine judgment call, because the dud shares can be on the cusp of a brilliant recovery. In some cases, their worth has been further devalued by EOFY selling that in theory will ease after June 30. But for investors sitting on capital gains from an AI driven splurge on data centres or a fear-driven plunge into gold, offsetting the gains by selling the lost causes makes sense. Or maybe hey want to lighten up on Commonwealth Bank (ASX:CBA) shares and offset the healthy gains Investors must ensure they are genuinely exiting the position, with the taxman's 'wash' rules preventing repurchasing within 45 days. Even then, investors must justify their action, such as independent research changing a call on a stock from 'sell' to 'buy'. Domino's prospects are as flat as its pizza Amid a string of downgrades, Domino's Pizza Enterprises (ASX:DMP) shares have lost 88% of their value since peaking in September 2021. Domino's problems include underperforming French and Japanese operations, while measures including store closures have failed to turn the company's fortunes. Long-time CEO Don Meij departed in November last year, while the Europe and Japan chiefs have also left the building. As with McDonald's decades previously, Dominos mastered the art of industrial scale, ultra fast production. Maybe the world has reached peak pizza … if that's possible. Busted flush Having seen 70% of the value of their holdings vanish over the past year, Star Entertainment Group (ASX:SGR) investors would have been better off at the blackjack table … and that's not saying much. The owner of gambling dens in Sydney, Brisbane and the Gold Coast, Star was crippled by money laundering and other governance controversies. Star is subject to a convertible note/debt-based rescue bid from US casino operator Bally's Corporation. An independent expert report dubs the proposal as 'not fair' to shaeholders but 'compelling' nonetheless, given the company's dire position. Investors should take the hint. Also pinged for money laundering transgressions, SkyCity Entertainment Group (ASX:SKC) last month warned of 'deteriorating' trading conditions at its Auckland and Adelaide casinos. Skycity shares have fallen 36% over the year. Morningstar dubs them as 'materially undervalued', but the company's luck doesn't look like turning any time soon. A sobering lesson Shares in overseas student wrangler IDP Education (ASX:IEL) plunged 50% after a June 3 profit warning, erasing $1 billion of value. IDP has nowhere to run, with its key geographies of Canada, Australia, the UK and the US all executing migration crackdowns. Overseas students made for a once thriving export industry, but the crackdown has cooked and plucked that golden goose. IDP remains the industry leader and management points to a recovery. The stock remains one class worth wagging, in our humble view. The stock has lost an astonishing 75% over the last year. Shooting Bambi Selling CSL (ASX:CSL) shares is like shooting Bambi, given the almost certain demand for its life-saving plasma derived products. Once the biggest ASX company, CSL has lost 17% of its value because of weakness in its Seqirus flu vaccine division and its acquired Vifor kidney health arm. Lingering concerns over Donald Trump's tariff and drug pricing have also weighed on sentiment. Broker Wilsons describes CSL as 'thorougly over owned'. But - hey - the experts said the same about CBA shares, which continue to defy gravity. Cochlear (ASX:COH) shares also are off the pace. In an earnings downgrade last week, the company noted weakness in developed markets for implant and sound processor sales. New implant and processor products might put things right, but so far investors aren't listening. Small cap cleanout candidates Call recording house Dubber Corp (ASX:DUB) in March 2024 discovered that $30 million of funds had gone missing. This week, the company said it would sue its external auditors over the unrecovered $26.6 million. But with investors sitting on an 80% loss since the incident, they probably should hang up. In the retail sector, shares in plus-sized clothier City Chic Collective (ASX:CCX) have shrunk 35% over the year and 97% over five years. The company recently warned of poor trading here and in the US, while tariffs are a worry. Weight Watchers filed for US bankruptcy in May and Ozempic sales are booming, so maybe there's a nexus. Owner of Kathmandu, KMD Brands (ASX:KMD) on Thursday signalled peak puffer jacket with a weak earnings outlook.
News.com.au
3 hours ago
- News.com.au
Waverley Park: AFL likely to snap up historic Hawks' home
Melbourne's historic Waverley Park may not be lost to football, with the AFL firmly in the race to purchase the venue from Hawthorn. It would be the league's second major piece of infrastructure, following their purchase of Marvel Stadium in Docklands for more than $30m in 2016. Expressions of interest for the property closed on April 3, and a deal is expected to be finalised within a matter of days. Actor Shane Jacobson reveals plans after buying country Vic pub Industry sources have indicated the property had attracted significant interest, but the AFL was the frontrunner. They also confirmed the sales price would likely fall in the $10m to $20m range. Hawthorn purchased the ground for just $1 in 2006, with the club set to cash in big-time on any sale. Commercial real estate agency Colliers' director Ben Baines, Victorian chief executive Rob Joyes and executive Lucas Soccio, who have the listing, declined to comment. The offering includes the Hawks' soon-to-be former training and administrative headquarters set within the within the Sir Kenneth Luke Stand, with the club set to move to a purpose-built new Dingley Village site this year. Features of Waverley Park include a full-size MCG-specification oval on the title, a gym, 25m-long heated indoor pool, running track, medical treatment rooms and 48 basement car spaces. But the listing does not include the famous oval that hosted more than 730 AFL and VFL games, including the 1991 AFL grand final. While the venue once had a capacity of 72,000 people, much of the stadium has since been demolished and is now surrounded by a housing estate. The AFL said only on Friday night that it was always looking for more facilities to accommodate the growth of the game. 'The AFL has targeted having 10 million attendees at AFL/AFLW games, events or festivals, two million AFL club members and one million participants and in order to achieve the target for participation we need two ovals a week every week for the next five years,' AFL spokesman Jay Allen said. 'We are always looking for ovals, either already in the system that we can continue to use for football, or new greenfield developments so we can continue to expand the space we need to accommodate the strong national growth in people playing our game.' Former footballer John Rombotis debuted at Waverley Park for Fitzroy in 1995, and had one of his best games in the AFL with Port Adelaide at the ground in 1997. Rombotis, now a real estate agent, said it was good to see the AFL taking an interest in the old ground – and noted that a purchase price under $20m would be just a fraction of what they were making at Marvel Stadium each year. Waverley Park also hosted the 2000 VFA/VFL premiership match, the last official game played there, and a KISS concert in the 1980s.
